{"nctId":"NCT00438360","briefTitle":"Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis","startDateStruct":{"date":"2006-05"},"conditions":["Chronic Plaque Psoriasis"],"count":243,"armGroups":[{"label":"Cyclosporine A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclosporine A microemulsion"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cyclosporine A microemulsion","otherNames":["Neoral"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Outpatients 18 years of age and older (max 65 years)\n* Patients with chronic plaque psoriasis on disease remission (i.e. PASI ≤75% of PASI before cyclosporine continuous treatment course) entering a maintenance period\n* Disease remission obtained with only cyclosporine as systemic therapy (maximum dose 5 mg/kg/day) for \\>8 weeks and \\<16 weeks\n* PASI still \\<75% of PASI before cyclosporine continuous treatment course, at randomization to study treatment (8±2 days after disease remission)\n\nExclusion criteria:\n\n* Abnormal renal function (creatinine ≥ 10% the upper limit of the reference range)\n* Severe chronic degenerative diseases\n* Severe uncontrolled hypertension\n* Body weigh \\>110 kg\n* Abnormal liver function\n* Hyperkalemia or hyperuricemia\n* Clinically significant impairment of hematopoietic and cardiovascular function\n* Concomitant therapy with nephrotoxic medications\n* Patients with malignancy or a history of malignancy\n* Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception\n* Clinically significant uncontrolled bacterial, viral or fungal infection\n* Evidence of drug and/or alcohol abuse","sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score","description":"PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score \\>75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was \\>= 75%. In all the other cases the patient was considered as success (no relapse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Clinical Relapse","description":"Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) \\>75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.369","spread":null},{"groupId":"OG001","value":"0.456","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Psoriasis Area and Severity Index (PASI) Score","description":"PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of the severest degree.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.70","spread":"8.0"},{"groupId":"OG001","value":"6.86","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis","description":"BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( \\[Height(in) x Weight(lbs) \\]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.12","spread":"12.9"},{"groupId":"OG001","value":"10.45","spread":"16.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus","description":"Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.32","spread":"30.9"},{"groupId":"OG001","value":"25.44","spread":"31.9"}]}]}]},{"type":"SECONDARY","title":"Safety / Tolerability Assessed by Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":160},"commonTop":["Abdominal pain upper","Hypertriglyceridaemia"]}}}